Dédée F. Murrell
A5000758369- Autoimmune Bullous Skin Diseases
- Skin and Cellular Biology Research
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Nail Diseases and Treatments
- Dermatology and Skin Diseases
- Platelet Disorders and Treatments
- Dermatological and Skeletal Disorders
- Hair Growth and Disorders
- Allergic Rhinitis and Sensitization
- Medicine and Dermatology Studies History
- melanin and skin pigmentation
- Cutaneous lymphoproliferative disorders research
- Cell Adhesion Molecules Research
- Diversity and Career in Medicine
- Asthma and respiratory diseases
- Nonmelanoma Skin Cancer Studies
- Drug-Induced Adverse Reactions
- Skin Protection and Aging
- Cutaneous Melanoma Detection and Management
- Psoriasis: Treatment and Pathogenesis
- Contact Dermatitis and Allergies
- Dermatologic Treatments and Research
- Eosinophilic Disorders and Syndromes
- Cancer and Skin Lesions
UNSW Sydney
2016-2025
St George Hospital
2016-2025
The George Institute for Global Health
2021-2025
Australasian Blistering Diseases Foundation
2025
St. George Hospital
2012-2024
Cancer Trials Australia
2021-2024
St George's Hospital
2007-2024
The University of Notre Dame Australia
2024
John Wiley & Sons (United States)
2019-2023
John Wiley & Sons (United Kingdom)
2019-2023
In the primary analysis of ERIVANCE BCC trial, vismodegib, first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) 30% 43% in metastatic basal cell carcinoma (mBCC) locally advanced (laBCC), respectively. ORRs investigator were 45% 60% (laBCC). Herein, we present long-term safety final investigator-assessed efficacy results patients with mBCC or laBCC. One hundred four measurable received oral...
Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions the mucous membranes skin. Before era immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate severe vulgaris in Europe United States.The Autoimmune blistering Task Force European Academy Dermatology Venereology...
Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis.We sought to evaluate a new dosing strategy of nemolizumab patients with AD.We performed 24-week, randomized, double-blind, multicenter study (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, topical corticosteroids adults moderate-to-severe AD, severe pruritus, inadequate control treatment (n = 226). The Eczema Area Severity Index (EASI), peak pruritus (PP) numeric rating...
Daylight photodynamic therapy (DL‐PDT) of actinic keratosis (AK) has shown preliminary efficacy and safety results comparable to conventional (c‐PDT), using methyl aminolevulinate (MAL) cream. To demonstrate the DL‐PDT vs. c‐PDT in treating mild facial/scalp AK. This 24‐week randomized, controlled, investigator‐blinded, multicentre, intra‐individual (non‐inferiority) (superiority regarding pain) study enrolled 100 subjects. AKs on face/scalp were treated once, with one side contralateral...
To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-related morbidity and GC-sparing ability of other therapies.Nineteen experts on GC use outcome measures from 11 subspecialties participated. Ten were the USA; nine Canada, Europe or Australia. Group consensus methods multicriteria decision analysis (MCDA) used. A Composite GTI Specific List comprise overall GTI. The reflects toxicity likely change during clinical trial. toxicities occur commonly, vary with...
To the Editor: With daily media warnings of a looming pandemic, physicians are understandably concerned about immunosuppressive or immunomodulating effects that might render patients receiving biologic therapies more susceptible to COVID-19 infection. At this early stage, we do not have specific data susceptibility virus, but on infectious complications for from their pivotal trials psoriasis. In Table I, compare overall infection rates as well upper respiratory infections and...
Abstract Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of skin and mucous membranes. This typically affects elderly presents with itch localized or, frequently, generalized bullous lesions. A subset patients only develops excoriations, prurigo‐like lesions, eczematous and/or urticarial erythematous The disease, which significantly associated neurological disorders, has high morbidity severely impacts quality life. Objectives methodology...
This guideline has been initiated by the task force Autoimmune Blistering Diseases of European Academy Dermatology and Venereology, including physicians from all relevant disciplines patient organizations. It is a S3 consensus-based that systematically reviewed literature on mucous membrane pemphigoid (MMP) in MEDLINE EMBASE databases until June 2019, with no limitations language. While first part this addressed methodology, as well epidemiology, terminology, aetiology, clinical presentation...
Abstract This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of European Academy Dermatology and Venereology (EADV) with a contribution physicians from all relevant disciplines patient organizations. It is S3 consensus‐based encompassing systematic review literature until June 2019 in MEDLINE EMBASE databases. first part covers methodology, clinical definition MMP, epidemiology, MMP subtypes, immunopathological...
background: Actinic keratosis (AK) is a very common condition, which has the potential of progressing to squamous cell carcinoma. The present study prospective, randomized comparing lesion response, cosmetic outcome, patient satisfaction and tolerability new treatment modality, photodynamic therapy (PDT), using topical methyl aminolevulinate (Metvix®), with most commonly used standard for AK, cryotherapy.methods: A total 204 patients clinically diagnosed AK were either cryotherapy or PDT....
Abstract The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence‐based dermatology. Harmonising Outcome Measures for Eczema ( HOME ) initiative an international multiprofessional group dedicated outcomes research. In June 2011, the conducted consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) determine...
Abstract Background Actinic keratoses are the most common actinic lesions on Caucasian skin. Cryosurgery with liquid nitrogen is commonly used to treat keratoses, but there have been few studies examining true rate of cure in everyday dermatologic practice. Aim To determine prospectively efficacy cryosurgery as a treatment for Methods A prospective, multicentered study (a subsidiary photodynamic therapy trial) was performed. Patients untreated greater than 5 mm diameter face and scalp were...